NCT01560403 - A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 21, 2012

Primary Completion Date

July 23, 2013

Study Completion Date

July 23, 2013

Conditions

Short Bowel Syndrome

Interventions

DRUG

Teduglutide

0.05 mg/kg/day subcutaneously taken once per day for 12 months

Trial Locations (5)

Mount Sinai Medical Center, New York

University of Pennsylvania, Philadelphia

Emory University School of Medicine, Atlanta

Vanderbilt University Medical Center, Nashville

Scripps Clinic & Research Foundation, La Jolla